FRC Logo
🔹
🔹
•

News

Latest Market News

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Kymera Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Kymera Therapeutics, Inc. (KYMR) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisKYMR

Kymera Therapeutics, Inc.

KYMR
Stock Price
$0.00
Updated 02:50 AM
Sign In
  • Phase 1 · Company Overview
  • Phase 2 · FRC Research
  • Phase 3 · Financial Data
  • Phase 4 · Peer Comparison
  • Phase 5 · Ownership & News
KYMR$0.00
Home🔹Stocks🔹Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMR•NASDAQ

Kymera Therapeutics, Inc.

KYMR•NASDAQ
Mkt Cap$4.63B
Sentiment

Kymera Therapeutics, Inc.

KYMR
Stock Price
$0.00
Updated 02:50 AM
Sign In
  • Phase 1 · Company Overview
  • Phase 2 · FRC Research
  • Phase 3 · Financial Data
  • Phase 4 · Peer Comparison
  • Phase 5 · Ownership & News
KYMR$0.00
Phase 1 · Company Overview
1

Step 1: Overview

What the company does, where it operates, and who runs it.

Overview for Kymera Therapeutics, Inc.

Industry:Biotechnology
Sector:Healthcare
CEO:Nello Mainolfi
Description:Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Address:200 Arsenal Yards Boulevard, Watertown, MA, US
2

Step 2: Infographics

Visual summary of the business at a glance.

Phase 2 · FRC Research
3

Step 3: Media

Videos and interviews covering the company.

Phase 3 · Financial Data
4

Step 4: Stock Data

Price chart, volume, and trading data.

KYMR Stock Price

5

Step 5: Fair Value

What FRC thinks the stock is worth vs. the current price.

6

Step 6: Financial Ratios

Profitability, returns, valuation, and leverage ratios.

7

Step 7: Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

8

Step 8: Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

9

Step 9: Financial Statements

Income statement, balance sheet, and cash flow statements.

Phase 4 · Peer Comparison
10

Step 10: Comparables

List of peer companies in the same industry.

Phase 5 · Ownership & News
12

Step 12: Institutional Ownership

Which funds and firms own the stock.

13

Step 13: Insider Trading

Recent buying and selling by company executives.

14

Step 14: Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

15

Step 15: News

Latest headlines and market coverage.

News

Latest Market News

News

Latest Market News